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Abstract
Background: Treprostinil is a prostacyclin analog used to treat portopulmonary 
hypertension (PPHTN) and is one of several drugs shown to increase survival, but 
results in platelet dysfunction. Little is known about the management of patients on 
treprostinil who present with an acute subdural hematoma (aSDH). We describe 
such a case and offer our recommendations on management based on our 
experience and review of the literature.
Case Description: A 63‑year‑old, right‑handed female with a history of PPHTN 
presented with severe headache and was found to have a large left aSDH with 
midline shift on imaging. She was admitted to the neurosurgical intensive care 
unit (ICU) where she developed hemiparesis and subsequently underwent emergent 
decompression. Postoperatively she improved, but several hours after became 
obtunded and imaging showed reaccumulation of the aSDH, which required 
reoperation. At 6 months postoperatively she had only a mild hemiparesis and was 
being reconsidered for treprostinil therapy as a bridge to liver transplant. Only one 
paper in the literature thus far has reported a patient with an aSDH managed with 
treprostinil. The authors achieved adequate intraoperative hemostasis without the 
use of platelet transfusion and lack of complications intraoperatively.
Conclusion: While concerns related to the risk of bleeding in surgery are valid, 
intraoperative hemostasis does not appear to be profoundly affected. Surgical 
intervention should not be delayed and prostanoid therapy discontinued, if 
possible, postoperatively. Patients should be placed in an intensive care setting 
with assistance from pulmonary specialists and close monitoring of neurological 
status and blood pressure.
Key Words: Acute subdural hematoma, portopulmonary hypertension, prostanoid 
therapy, pulmonary arterial hypertension, treprostinil
INTRODUCTION
The patient with acute subdural hematoma (aSDH) often 
constitutes a neurosurgical emergency; however, many 
cases are managed conservatively.[2] Patients who present 
with an aSDH less than 1 cm in maximum thickness, 
less than 5 mm of midline shift and no neurologic deficit 
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can be managed without immediate surgery. Those who 
develop a diminished level of consciousness or other 
neurologic deficit should receive surgical intervention. 
It has been estimated that by 2030 aSDH evacuation 
will be the most common neurosurgical procedure due 
to shifts in demographics and the number of people 
taking oral anticoagulants or affected by coagulopathy.[10] 
More frequently, neurosurgeons are faced with complex 
decision making due to intracranial hemorrhage, 
particularly in patients with aSDH. This case report 
and brief literature review serve as an introduction to 
portopulmonary hypertension (PPHTN), its proposed 
pathophysiology, common treatments, and our experience 
in the neurosurgical treatment of a patient with aSDH 
and PPHTN.
CASE PRESENTATION
History
A 63‑year‑old, right‑handed female presented with new 
complaints of shortness of breath, nausea, vomiting, 
and severe progressive headache over the course of 
3 weeks. Her past medical history was complicated with 
a longstanding history of hepatitis C acquired from 
a blood transfusion in the 1970s. Unfortunately, she 
developed end‑stage liver disease, cirrhosis, PPHTN, and 
coagulopathy. Her neurologic examination was grossly 
intact. A computed tomography (CT) scan of the head 
demonstrated a 13‑mm, left‑sided lentiform‑shaped 
hyperdensity suggestive of subdural hematoma with 
midline shift of 7 mm and minimal transtentorial 
herniation [Figure 1a]. She had an international 
normalized ratio (INR) of 1.55 and a platelet level of 
47,000/µL. At the time of our consultation, she was 
undergoing a continuous treprostinil infusion and taking 
oral sildenafil for PPHTN. The patient was admitted to 
the intensive care unit (ICU) and medical, hepatology, 
and pulmonary consultations were sought. Fresh frozen 
plasma (FFP) and platelets were administered, and she 
was monitored closely. According to our critical care 
colleagues, the treprostinil could not be discontinued. 
Repeat laboratory studies yielded an INR of 1.50 and a 
platelet level of 90,000/μL. Over the ensuing 10 h, her 
level of consciousness diminished and she acquired 
mild right‑sided hemiparesis. Most concerning was the 
development of an enlarged left pupil. Repeat head CT at 
that time revealed the SDH had increased to a maximum 
width of 16 mm and midline shift of 9.5 mm [Figure 1b].
Operative findings
She was taken to the operating room for a left 
frontotemporoparietal craniotomy and evacuation of 
the subdural clot. A small, bleeding pial artery that 
had coagulated was the likely source of the hematoma. 
Treprostinil infusion and sildenafil were continued 
throughout the surgery. Intraoperatively, hemostasis was 
obtained in routine fashion without undue burden from 
excessive bleeding. The brain was nicely pulsatile at the 
conclusion of surgery, a patch duraplasty loosely sewn, 
and the bone flap replaced. Tack‑up sutures were used, 
and a subgaleal drain was left behind. Postoperatively she 
had an INR of 1.45 and a platelet count of 136,000/µL. 
She awoke immediately and began following commands. 
Her anisocoria and weakness improved. She became 
obtunded several hours after the operation and showed 
signs of herniation (Glasgow Coma Scale 4). A head 
CT scan demonstrated a large extra‑axial hyperdense 
fluid collection with a midline shift of 19 mm in the 
same location as the SDH [Figure 1c]. She was taken 
emergently to the operating room for reopening of 
the craniotomy and evacuation of the hematoma. On 
repeat operation hemostasis was more challenging. 
The scalp, temporalis muscle, and external dural 
surface were hemorrhaging diffusely. The hematoma 
was found in the epidural space, and it was evacuated. 
There was no significant blood in the subdural space. 
The coagulopathy was felt to be qualitative, and 
cryoprecipitate, FFP, and additional platelets were 
administered in an effort to obtain hemostasis. Various 
techniques and products including bipolar electrocautery, 
irrigation, thrombin‑soaked Gelfoam® (Pfizer), Gelfoam 
Powder® (Pfizer), Avitene™ (Davol, Inc.), and Floseal 
Hemostatic Matrix (Baxter BioSurgery) were utilized 
to stop the bleeding. At the conclusion of the case the 
brain was again found to be pulsatile and the decision 
was made not to replace the bone flap. Subdural and 
subgaleal drains were placed and the wound was closed 
using a 2‑0 Vicryl™ (Ethicon) on a CT‑1 needle and then 
stapled. In the first hours postoperatively, she began to 
Figure 1: Initial CT findings of left frontoparietal extra-axial 
hyperdensity and accompanying left-to-right shift of the ventricular 
system representing an acute SDH and its resultant mass effect 
(a) with subsequent progression (b). Following craniotomy and 
bone flap replacement there is recurrence (c). After reoperation 
for craniectomy, ventricles assume a more midline position (d). 
2 months postoperatively, the brain has a sunken appearance 
and residual postoperative fluid has disappeared (e). Following 
cranioplasty the brain assumes its normal appearance (f)
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follow commands and move all of her extremities with 
strength. Her treprostinil and sildenafil were continued.
Postoperative course
A postoperative CT scan demonstrated resolution of 
midline shift and some persistent fluid within the 
operative bed [Figure 1d]. Her INR measured between 
1.4 and 1.7 throughout the remainder of her hospital stay, 
which lasted just over 1 month. Platelet counts remained 
between 45,000 and 225,000/µL. Multiple platelet 
function assays demonstrated dysfunctional platelets 
while on treprostinil infusion therapy. She was weaned 
from the ventilator and began to eat. Given her acute 
medical condition she was no longer a candidate for 
liver transplant. Over the course of several weeks in the 
hospital she was weaned from the treprostinil infusion 
and the tunneled infusion catheter removed. She was 
transferred to inpatient rehabilitation and eventually was 
discharged home. Her 2‑month postoperative scan showed 
resolution of fluid in the operative bed [Figure 1e]. She 
underwent cranioplasty roughly 6 months after the initial 
surgery [Figure 1f]. At that time, she had stable mild 
right hemiparesis and was ambulatory with a walker. 
Currently, she is being considered for rechallenge with 
treprostinil therapy as a bridge to liver transplant.
DISCUSSION
The common pathophysiology in idiopathic pulmonary 
arterial hypertension (iPAH) and PPHTN results from 
diminished levels of endogenous eicosanoids produced in 
pulmonary vascular endothelial cells, which contributes 
to a high mean pulmonary arterial pressure and increased 
pulmonary vascular resistance.[7,8] Because of this 
prostanoid therapies have been studied since the 1980s 
and approved by the Food and Drug Agency (FDA) for 
the treatment of PAH in the mid 1990s.[4,7] Epoprostenol 
has been shown to improve exercise capacity, lower 
pulmonary artery pressure (PAP), and improve survival 
as well as reduce all‑cause mortality in prospective 
randomized trials of PAH.[4,5,7] Subsequent research 
focused on subcutaneous and intravenous treprostinil — 
a more stable pharmacologic analog of epoprostenol — 
that likewise demonstrated improved quality of life and 
survival (91–72% over 1–4 years).[3,7] Trials of prostanoid 
therapy in PPHTN patients have also demonstrated 
improved hemodynamic and functional responses with 
treatment.
Prostacyclin analogs function primarily via the 
prostaglandin receptor on vascular smooth muscle 
cells.[8,9] This leads to elevated levels of cyclic adenosine 
monophosphate via activation of intracellular adenylate 
cyclase which, in turn, induces smooth muscle 
relaxation. The inhibition of thromboxane‑mediated 
platelet activation and nitric oxide‑ and 
endothelin‑receptor‑mediated vasodilation of pulmonary 
and systemic vascular endothelium are other notable 
effects.[8,9]
In the literature abrupt cessation of prostanoid 
therapy has been associated with rebound systemic 
and pulmonary hypertension.[7,14‑17,19] This results in 
increased right ventricular afterload and subsequent 
decreased pump function borne out by echocardiogram 
demonstrating right heart dysfunction and mitral valve 
regurgitation. Clinically, patients may manifest a triad 
of decreased PAP, increased central venous pressures, 
and profound hypotension.[1] Severe dyspnea and chest 
discomfort are often seen in the nonintubated patient. 
Rebound pulmonary hypertension leading to right 
heart failure usually responds to inotropes, sedation, 
and resumption of prostanoid therapy. However, 
other treatments have been shown to be effective 
including digoxin, inhaled nitric oxide, high frequency 
ventilation with minimization of positive end‑expiratory 
pressure (PEEP), and treatment with oral (bosentan, 
ambrisentan) and intravenous (tezosentan) 
endothelin receptor antagonists (ERAs). High‑dose 
phosphodiesterase‑5 (PDE5) inhibitors like sildenafil and 
angiotensin II‑receptor antagonists have all been shown to 
significantly ameliorate the effects of rebound pulmonary 
hypertension or right heart failure.[1,6,12,13,20] Additionally, 
cessation of beta‑blocker therapy and avoidance of 
calcium channel blockers should be encouraged as 
they decrease inotropicity and diminish preload, 
respectively.[11,14,17] All patients should have vital signs, 
electrolytes, and arterial blood gas (if ventilated) closely 
monitored to prevent hypothermia (increases pulmonary 
vascular resistance), hypotension (decreases preload), 
hypercarbia, hypocalcemia, hyperkalemia, and acidosis.[17]
Even if rapid prostanoid cessation is not an option 
we recommend treating these patients aggressively 
— meaning limited unnecessary delay in reversal of 
coagulopathy prior to operative intervention. Safain et al. 
successfully treated a patient with iPAH on treprostinil 
with surgery and concluded that intraoperative hemostasis 
was not problematic, a finding we corroborate.
Specific steps can be taken during surgery to minimize 
the risk of reaccumulation requiring reoperation. The use 
of a subdural and subgaleal drain with consideration of 
craniectomy during the first operation may ameliorate 
the need to return to the OR if bleeding continues after 
initial surgery. We placed tack‑up sutures in the first 
operation; however, the duraplasty was not closed at all 
the edges and a potential space remained between the 
bone and duraplasty that allowed blood to accumulate. 
It would have been safer to sew a watertight patch 
duraplasty with enough room for some expansion of 
the brain. With a duraplasty, aggressive tacking of the 
dura to the bone flap for obliteration of any potential 
epidural space would have made it more difficult for 
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epidural hematoma formation. Placement of both 
subdural and subgaleal drains may have saved our patient 
from a repeat operation. During the second operation, 
we found the use of 2‑0 Vicryl™ (Ethicon) on a CT‑1 
needle helped to ensure deep galeal, hemostatic stitches 
were placed in a swollen scalp, thus limiting the risk 
of epidural hematoma. The use of irrigation with a 
thrombin solution at the time of surgery for SDH has 
been described in patients with liver cirrhosis and is also 
an option as the technique resulted in an absolute risk 
reduction for recurrence of 20%.[18] Blood pressure control 
and adequate postoperative sedation also play important 
roles in the prevention of rebleeding.
CONCLUSION
This report now represents the second published case 
of a surgically treated aSDH in a patient on prostanoid 
therapy and the first such case in end‑stage liver disease 
and PPHTN. While concerns related to the risk of 
bleeding in surgery are valid, intraoperative hemostasis 
does not appear to be profoundly affected in patients 
taking prostanoid medications. Therefore, these patients 
should be operated on like any other patient with 
aSDH requiring surgery. If prostanoid therapy can be 
discontinued, we recommend careful monitoring in an 
ICU setting with assistance from neurocritical care and 
pulmonary specialists. There are a variety of critical 
care steps and technical nuances that can be employed 
to maximize patient care in this setting. The authors 
encourage other physicians to share their experiences 
with difficult cases so that patients may benefit.
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